Could a common sleep drug fight Alzheimer's? new trial aims to find out

NCT ID NCT06274528

Recruiting now Disease control Sponsor: University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study tests whether the sleep medication lemborexant (Dayvigo) can reduce levels of amyloid-beta and tau proteins in the blood and spinal fluid of older adults. These proteins are linked to Alzheimer's disease. The trial will enroll 201 healthy volunteers aged 65 and older, giving them either lemborexant or a placebo for six months to measure changes in these biomarkers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: lemborexant (Dayvigo)
What this could lead to: If it works, this could point toward a way to slow Alzheimer's by improving sleep and reducing harmful brain proteins.
What could go wrong: This is an early phase 2 trial, so results are not yet proven. The drug may not lower biomarkers enough, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Washington University in St. Louis, School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.